Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (Triple Body) is designed to be expressed as two polypeptide chains respectively. The Fd fragment and LC from an anti-EGFR antibody are both extended with the scFv fragment from an anti-IGF1R antibody. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY